Description

Molecular Details of Tirzepatide

• Molecular Formula:
  C225H348N48O68

• Molecular Weight (Monoisotopic):
  4813.52 g/mol

• Peptide Type:
  Synthetic dual incretin mimetic
  Acts as a GLP-1 receptor agonist and a GIP receptor agonist

• Structure Modifications:

  • 39–amino acid peptide backbone

  • Contains non-natural amino acids for stability

  • Conjugated with a C20 fatty diacid moiety for albumin binding → extends half-life (~5 days)

  • Allows once-weekly administration in research and clinical use

🧬 Mechanism of Action (Research Use Only):

• GLP-1 receptor agonism: Stimulates insulin secretion, reduces appetite, slows gastric emptying

• GIP receptor agonism: Enhances insulin response, promotes fat metabolism

• Synergistic dual action → superior weight reduction and glucose regulation compared to GLP-1 agonists alone (e.g., semaglutide)

🧪 Research Applications:

• Type 2 diabetes research (glucose regulation, beta-cell function)

• Obesity and metabolic health studies (weight reduction, fat metabolism)

• Comparative efficacy studies vs. semaglutide and retatrutide

• Cardiovascular outcomes (lipids, blood pressure, insulin resistance)

📑 Storage & Handling (Research Use Only):

• Form: Lyophilized peptide powder

• Common Dosages (research vials): 2 mg, 5 mg, or 10 mg

• Storage:

  • Lyophilized: Store at −20 °C

  • Reconstituted: Store at 2–8 °C (stable 7–14 days)

• Reconstitution: Sterile bacteriostatic water

• Solubility: Water-soluble

• Use: For laboratory research only. Not for human or veterinary use.